HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Budd-Chiari syndrome in a patient with factor V Leiden--successful treatment by TIPSS placement followed by liver transplantation.

Abstract
The causes of Budd-Chiari syndrome (BCS) comprise several diseases leading to thrombophilia. One of the most common thrombophilic disorders is resistance against activated protein C, caused by a single point mutation of the factor V gene. In December 1993, a 22-year-old patient was given a diagnosis of subacute BCS with occlusion of all major hepatic veins. Placement of a transjugular intrahepatic portosystemic stent shunt led to rapid disappearance of ascites and hepatic encephalopathy. During the following two years, recurrent partial occlusions of the shunt were treated by balloon angioplasty. The cause of the BCS still being unknown, in October 1996 we performed extensive laboratory investigations concerning states of thrombophilia and found moderately elevated IgG anticardiolipin antibodies (19.7 U/ml) and a resistance against activated protein C caused by heterozygosity for a point mutation of the factor V gene (1691G-->A; factor V Leiden). As a consequence, oral anticoagulation with coumarin was initiated. In October 1997, elective liver transplantation was performed which led to disappearance of APC resistance. Moreover, IgG anticardiolipin antibodies have been negative since then. If BCS is caused by APC resistance, liver transplantation not only treats the chronic liver disease but also cures the state of thrombophilia since factor V is mainly synthesized in the liver.
AuthorsW Avenhaus, H Ullerich, J Menzel, E C Foerster, K Hengst, W Domschke
JournalZeitschrift fur Gastroenterologie (Z Gastroenterol) Vol. 37 Issue 4 Pg. 277-81 (Apr 1999) ISSN: 0044-2771 [Print] Germany
PMID10378363 (Publication Type: Case Reports, Journal Article)
Chemical References
  • factor V Leiden
  • Factor V
Topics
  • Activated Protein C Resistance (genetics)
  • Adult
  • Budd-Chiari Syndrome (blood, genetics, therapy)
  • Combined Modality Therapy
  • Factor V (genetics)
  • Humans
  • Liver Transplantation
  • Male
  • Point Mutation
  • Portasystemic Shunt, Transjugular Intrahepatic
  • Prognosis
  • Thrombophilia (genetics, therapy)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: